Injectable Glutathione Mechanisms and Clinical Applications

Fundamental Biochemical Mechanisms

GSH serves as an essential cofactor for glutathione peroxidase (GPX4), which catalyzes the reduction of hydrogen peroxide (H₂O₂) to water and lipid peroxides (PLOOH) to lipid alcohols, preventing membrane damage and ferroptosis, as supported by the Cell Death and Differentiation and Autophagy journals 2, 3
Glutathione peroxidase requires selenium for optimal enzymatic activity, making adequate selenium status crucial for GSH function, according to Praxis Medical Insights 4
GSH protects against lipid peroxidation by converting oxidized glutathione disulfide (GSSG) back to its reduced form through glutathione reductase, which requires NADPH as a cofactor, as reported in Cell Death and Disease and Cell Death and Differentiation journals 5, 2

GSH distributes to tissues where it participates in detoxification reactions through glutathione S-transferase (GST)-catalyzed conjugation of electrophilic compounds, as described in Environmental Health Perspectives 6, 7
Erythrocytes rely heavily on GSH for survival since they lack mitochondria and peroxisomes but contain high iron levels from hemoglobin, making them vulnerable to oxidative stress, according to Cell Death and Disease 5

For platinum-based chemotherapy (cisplatin/oxaliplatin), injectable GSH (1.5-2.5g IV before chemotherapy) may reduce peripheral neuropathy through detoxification of platinum-induced reactive intermediates, though five small trials showed benefit while one larger trial with paclitaxel/carboplatin showed no benefit, as reported in the Journal of Clinical Oncology and Praxis Medical Insights 8, 1
The American Society of Clinical Oncology states GSH is ineffective for taxane-induced neuropathy prevention, suggesting the mechanism differs between platinum and taxane neurotoxicity, according to the Journal of Clinical Oncology and Praxis Medical Insights 8, 1

GSH conjugates with toxic metabolites and xenobiotics through GST enzymes, creating water-soluble compounds that are transported out of cells, protecting against chemical-induced cellular damage, as described in Environmental Health Perspectives 6, 7
Different GST isoenzymes (Alpha, Mu, Pi, Theta, Zeta) exhibit varying catalytic efficiency for different substrates, with some showing preference for specific carcinogenic metabolites, according to Environmental Health Perspectives 6, 7

No pharmacokinetic data exists for subcutaneous bioavailability of glutathione, and no sterile pharmaceutical-grade formulations are designed for subcutaneous use, as stated in Praxis Medical Insights 1
Subcutaneous administration carries risks of injection site reactions, tissue irritation, abscess formation, and unknown systemic absorption rates, according to Praxis Medical Insights 1
Only intravenous administration has established evidence in medical literature—subcutaneous injection is not discussed in any guideline or high-quality research, as reported in Praxis Medical Insights 1
During active cancer treatment, most oncologists advise against high-dose antioxidant supplementation (including GSH) during chemotherapy or radiotherapy, as antioxidants may protect cancer cells from oxidative damage that contributes to treatment effectiveness, according to Praxis Medical Insights 9
GSH should not be confused with glutamine—they are different compounds with distinct indications and dosing regimens, as stated in Praxis Medical Insights 1
For cystic fibrosis patients, no data supports glutathione therapy and supplementation is not recommended, according to Praxis Medical Insights 1